Generics - Daiichi Sankyo

Filter

Current filters:

Daiichi Sankyo

Popular Filters

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

Troubled Ranbaxy to be acquired by Sun Pharma for around $4 billion

07-04-2014

In something of a surprise announcement, Sun Pharmaceutical Industries revealed this morning that it…

Daiichi SankyoGenericsIndiaMergers & AcquisitionsRanbaxy LaboratoriesSun Pharmaceuticals

Ranbaxy temporarily suspends shipments from Toansa and Dewas plants

25-02-2014

Indian drugmaker Ranbaxy Laboratories has announced in a letter to the Stock Exchange that it has temporarily…

Asia-PacificDaiichi SankyoGenericsIndiaProductionRanbaxy Laboratories

Ranbaxy rises on 4th-qtr performance, but can this continue?

Ranbaxy rises on 4th-qtr performance, but can this continue?

05-02-2014

Ranbaxy Laboratories, India’s largest generic drugmaker by sales, saw its shares rise 5.6% to 340 rupees…

Daiichi SankyoFinancialGenericsRanbaxy Laboratories

Another ban by US FDA on a Ranbaxy production facility

Another ban by US FDA on a Ranbaxy production facility

24-01-2014

As if the Indian drug major has not had enough negative news from the US regulator, the US Food and Drug…

Asia-PacificDaiichi SankyoGenericsIndiaNorth AmericaProductionRanbaxy LaboratoriesRegulationUSA

Ranbaxy cleared to market branded generic of Aricept in Canada

Ranbaxy cleared to market branded generic of Aricept in Canada

08-01-2014

The Canadian subsidiary of Ranbaxy Laboratories has received approval to manufacture and market RAN-Donepezil…

AriceptCanadaDaiichi SankyoEisaiGenericsNeurologicalNorth AmericaRAN-DonepezilRanbaxy LaboratoriesRegulation

Ban on FDA-regulated drugs from Ranbaxy's Mohali plant

17-09-2013

There was another blow for India's largest drugmaker Ranbaxy Laboratories (BSE: 500359) yesterday (September…

Asia-PacificDaiichi SankyoGenericsNorth AmericaProductionRanbaxy LaboratoriesRegulation

Ranbaxy highlights its actions on improved business and quality assurance

23-05-2013

Indian drugmaker Ranbaxy Laboratories (BSE: 500359), whose US subsidiary was the subject of the biggest…

Daiichi SankyoGenericsManagementProductionRanbaxy LaboratoriesRegulation

US DoJ says Ranbaxy pleads guilty and agrees to pay $500 million in settlements

14-05-2013

In the largest drug safety settlement to date with a generic drug manufacturer, Ranbaxy USA, a subsidiary…

Asia-PacificDaiichi SankyoFinancialGenericsLegalNorth AmericaProductionRanbaxy LaboratoriesRegulation

Daiichi Sankyo and Ranbaxy to launch branded generics in Brazil

21-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority (64%)-owned Indian affiliate Ranbaxy…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Ranbaxy in deal with Alembic to market bioequivalent Pristiq in USA

05-03-2013

The US subsidiary of India's largest drugmaker, Ranbaxy Laboratories (AB: BO), which is majority owned…

Alembic PharmaceuticalsDaiichi SankyoGenericsLicensingMarkets & MarketingNeurologicalNorth AmericaPatentsPfizerPristiqRanbaxy Laboratories

Daiichi Sankyo and Ranbaxy combine business operations in Thailand

16-01-2013

Japanese pharma major Daiichi Sankyo (TYO: 4568) and its 64%-owned affiliate Ranbaxy Laboratories (AB:…

Asia-PacificDaiichi SankyoGenericsManagementMarkets & MarketingPharmaceuticalRanbaxy Laboratories

Ranbaxy Labs' Absorica debuts in USA

27-11-2012

Indian drugmaker Ranbaxy Laboratories (AB: BO), which is majority owned by Japan's Daiichi Sankyo, said…

AbsoricaCipher PharmaceuticalsDaiichi SankyoDermatologicalsGalephar Pharmaceutival ResearchGenericsMarkets & MarketingNorth AmericaPharmaceuticalRanbaxy Laboratories

Ranbaxy gains approval for new manufacturing plant in Malaysia

14-09-2012

India's largest drugmaker Ranbaxy Laboratories (AB: BO). said yesterday that the government of Malaysia…

Asia-PacificDaiichi SankyoGenericsProductionRanbaxy Laboratories

US FDA pulls 27 Ranbaxy ANDAs approvals under consent decree

23-08-2012

The Food and Drug Administration is withdrawing approval of 27 Abbreviated New Drug Applications (ANDAs)…

Antibiotics and Infectious diseasesDaiichi SankyoDiabetesGenericsNorth AmericaRanbaxy LaboratoriesRegulation

Daiichi Sankyo and Ranbaxy debut hybrid business model in Venezuela

20-06-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) announced that its Daiichi Sankyo Venezuela unit would…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Ranbaxy sales rocket 55%, net rises four-fold

11-05-2012

Ranbaxy Laboratories (AB: BO), India's largest drugmaker, came in with a stompingly good set of financial…

Daiichi SankyoFinancialGenericsRanbaxy Laboratories

Daiichi Sankyo and Ranbaxy launch Sevikar in Romania

19-04-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned Indian subsidiary Ranbaxy Laboratories…

Cardio-vascularDaiichi SankyoEuropeGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSevikar

Ranbaxy opens new plant in Morocco

12-03-2012

Ranbaxy Morocco, a unit of India's largest drugmaker Ranbaxy Laboratories (AB: BO), which is majority…

Daiichi SankyoGenericsMarkets & MarketingRanbaxy LaboratoriesRest of the World

Ranbaxy debuts generic Lipitor in Germany, ahead of patent expiry

07-03-2012

The German subsidiary of India's Ranbaxy Laboratories (AB: BO), Basics GmbH located in Leverkusen, yesterday…

atorvastatinBasics GmbHCardio-vascularDaiichi SankyoEuropeGenericsLipitorMarkets & MarketingPfizerRanbaxy Laboratories

Ranbaxy posts $586 million loss due to charges

23-02-2012

India’s largest drugmaker Ranbaxy Laboratories (RAB: BO), which is 64% owned by Japan’s Daiichi…

Daiichi SankyoFinancialGenericsRanbaxy Laboratories

Ranbaxy signs consent decree with US FDA over production practices

22-12-2011

India’s largest drugmaker Ranbaxy Laboratories (RANB: BO), which is 64% owned by Japan’s Daiichi…

Daiichi SankyoFinancialGenericsLegalNorth AmericaPharmaceuticalRanbaxy LaboratoriesRegulation

Daiichi Sankyo extends reach in Italy, with Ranbaxy to market its products

05-10-2011

The Italian subsidiaries of Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned India-based…

Cardio-vascularDaiichi SankyoEuropeGenericsMarkets & MarketingRanbaxy Laboratories

Back to top